Literature DB >> 22976314

Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues.

N Unger1, B Ueberberg, S Schulz, W Saeger, K Mann, S Petersenn.   

Abstract

5 Human somatostatin receptor subtypes (sst1-5) mediate the antisecretory and antiproliferative effects of somatostatin. We examined somatostatin receptor protein expression in 28 human normal tissues. Immunostaining was performed with specific polyclonal antibodies for sst1-5. Staining pattern and distribution of ssts were evaluated. Anterior pituitary was positively stained for all 5 ssts. Pancreatic islets exhibited a positive staining for sst1-3 and sst5. Adrenal cortex expressed all 5 receptor subtypes, while the medulla was positive for sst3 and sst5 only. The thyroid expressed sst5 only, limited to single interfollicular cells. All 5 ssts were detected in the ovary, limited to luteinized granulosa cells of the corpus luteum. In the testis, sst2A was detected in the basal parts of the tubules, while sst5 was positively stained in the luminal parts. Sst1 was found in Leydig cells only. Stomach was positively stained for all 5 ssts. Investigation of the kidney revealed differential expression, with sst2A being found in the glomerules. The tubules expressed all 5 ssts. In the bone marrow cells of the granulocytopoiesis expressed sst2A only. The cerebellum expressed sst5 in a certain cell type, representing presumably Purkinje cells, while sst2A was stained in intercellular fibers. The expression of somatostatin receptor subtypes in a variety of human normal tissues may indicate a physiological role in these organs. Somatostatin analogues may offer new diagnostic and therapeutic implications for tumours related to these tissues. However, treatment of defined tumours with somatostatin analogues may also alter other normal tissues. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22976314     DOI: 10.1055/s-0032-1314859

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  16 in total

1.  Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.

Authors:  L de la Cueva; P Lloro; M J Sangrós; L López Vélez; P Navarro; L Sarria; S Álvarez; D Abós
Journal:  Clin Transl Oncol       Date:  2017-01-31       Impact factor: 3.405

Review 2.  Somatostatin receptor expression in non-classical locations - clinical relevance?

Authors:  Eldrin Bhanat; Christian A Koch; Rinkuben Parmar; Vishnu Garla; Vani Vijayakumar
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 3.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

4.  Insulin-like factor 3 plasma levels in acromegaly before and after somatostatin analog treatment.

Authors:  Marco Rossato; Francesca Dassie; Valentina Silvestrin; Chiara Martini; Roberto Vettor; Pietro Maffei
Journal:  Endocrine       Date:  2014-06-12       Impact factor: 3.633

5.  Editorial : Neuroendocrine neoplasms.

Authors:  Christian A Koch; Stephan Petersenn
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

6.  Prevalence and quantitative analysis of indium-111 pentetreotide (Octreoscan) uptake in the pancreatic head on SPECT/CT imaging: establishing a region of interest-based pathological uptake threshold.

Authors:  Jamal J Derakhshan; Michael D Farwell
Journal:  Nucl Med Commun       Date:  2019-07       Impact factor: 1.690

7.  The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts.

Authors:  Carol A Nelson; Michael T Azure; Christopher T Adams; Kurt R Zinn
Journal:  J Nucl Med       Date:  2014-10-30       Impact factor: 10.057

Review 8.  Peptide Receptor Radionuclide Therapy in Thyroid Cancer.

Authors:  Sriram Gubbi; Christian A Koch; Joanna Klubo-Gwiezdzinska
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-30       Impact factor: 6.055

Review 9.  New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  J Neurooncol       Date:  2013-05-15       Impact factor: 4.130

10.  The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.

Authors:  Manel Puig-Domingo; Raúl M Luque; Jordi L Reverter; Laura M López-Sánchez; Manuel D Gahete; Michael D Culler; Gonzalo Díaz-Soto; Francisco Lomeña; Mattia Squarcia; José Luis Mate; Mireia Mora; Laureano Fernández-Cruz; Oscar Vidal; Antonio Alastrué; Jose Balibrea; Irene Halperin; Dídac Mauricio; Justo P Castaño
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.